Key result
Cardiac myosin inhibitors likely delay rather than replace septal reduction therapy in obstructive HCM.
This narrative review highlights that cardiac myosin inhibitors are likely to modify the timing of septal reduction therapy rather than replace it, emphasizing mechanism-based selection, multimodality imaging, and multidisciplinary expertise in obstructive hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Expanding options complicate treatment selection in obstructive HCM; leaves open the need for comparative trials of myosin inhibitors versus septal reduction.
Obstructive hypertrophic cardiomyopathy is characterized by dynamic left ventricular outflow tract obstruction that can cause substantial symptoms and morbidity. The expanding range of pharmacologic, surgical, and transcatheter options has made treatment selection increasingly complex. This narrative review examines conventional medical therapy, cardiac myosin inhibitors, surgical septal myectomy, alcohol septal ablation, and emerging investigational septal reduction strategies. It also discusses patient selection, procedural risks, multimodality imaging, and the importance of experienced hypertrophic cardiomyopathy centers. A targeted narrative search of English-language literature indexed in PubMed was conducted from April through 31 July 2026, considering clinical trials, observational studies, guidelines, and relevant reviews. Cardiac myosin inhibitors are likely to modify the timing of septal reduction therapy rather than replace it. Future progress will depend on mechanism-based treatment selection, appropriate early referral, rigorous validation of emerging procedures, and integration of advanced imaging and multidisciplinary expertise to match each patient with the most suitable therapy.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) conducted a review in Obstructive hypertrophic cardiomyopathy. Pharmacologic, surgical, and transcatheter septal reduction therapies (including conventional medical therapy, cardiac myosin inhibitors, surgical septal myectomy, alcohol septal ablation, and emerging investigational strategies) was evaluated. Cardiac myosin inhibitors are likely to modify the timing of septal reduction therapy rather than replace it in patients with obstructive hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: